Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan ALS Patient Group Petitions For Insurance Coverage For Edaravone

This article was originally published in PharmAsia News

Executive Summary

Japan's amyotrophic lateral sclerosis patient group petitioned to get insurance coverage for cerebral infarction drug Radicut (edaravone) injection for ALS treatment. Six patients and family members April 24 met Takao Watanabe, vice minister of the Ministry of Health, Labor and Welfare. The group complained that without insurance coverage, edaravone treatment costs ¥100,000 to ¥150,000 ($1,000 to $1,500) per month and many patients have to forgo the treatment. Watanabe said that clinical trials results have not proved efficacy of edaravone for ALS and the Ministry would consider other options to reduce patient costs. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts